Novartis Gilenya Approved With Advisory Panel-Enhanced REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA follows the advice of its Peripheral and Central Nervous System Drugs Advisory Committee to ask doctors to do a range of testing and monitoring when they prescribe the MS drug.
You may also be interested in...
Biogen Idec’s BG-12 Results Up The Ante In The Oral MS Market
The competitive profile of Biogen Idec Inc.’s BG-12 in the highly coveted and burgeoning market for oral multiple sclerosis drugs got a big boost April 21 with the release of better-than-expected additional monotherapy data from the Phase III DEFINE study.
Biogen Idec’s BG-12 Results Up The Ante In The Oral MS Market
The competitive profile of Biogen Idec Inc.’s BG-12 in the highly coveted and burgeoning market for oral multiple sclerosis drugs got a big boost April 21 with the release of better-than-expected additional monotherapy data from the Phase III DEFINE study.
Biogen Idec's BG-12 Results Up The Ante In The Oral MS Market
Biogen's drug is poised to become top dog among many oral MS drugs, including Novartis' approved Gilenya, analysts say.